1010836-56-2

Basic information

• Product Name: 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile
• Synonyms: 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile
• CAS NO: 1010836-56-2
• Molecular Formula: C7H11NO2
• Molecular Weight: 141.16774
• Mol File: 1010836-56-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 299.7±25.0 °C(Predicted)
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• PKA: 14.85±0.10(Predicted)
• CAS DataBase Reference: 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile(1010836-56-2)
• EPA Substance Registry System: 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile(1010836-56-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1010836-56-2(Hazardous Substances Data)

Usage

General Description

4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile, also known as HTPC, is a chemical compound with a molecular formula of C6H9NO2. It is a heterocyclic compound that contains a pyran ring with a hydroxymethyl and a carbonitrile functional group. 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile has potential applications in medicinal and pharmaceutical research, particularly in the development of new drugs. It is also used as a building block in organic synthesis and can be modified to create derivatives with different properties and functions. HTPC has attracted attention due to its unique chemical structure and potential for various applications in the field of chemistry and medicine.

Upstream product

• 30431-99-3 4-cyano-tetrahydro-pyran-4-carboxylic acid ethyl ester 
• 362703-30-8 methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate 

Downstream Products

• 1395997-00-8 methyl 6-(4-((4-cyanotetrahydro-2H-pyran-4-yl)methoxy)-2,6-difluorophenyl)-5-fluoropicolinate 

Relevant articles and documents

Synthesis of Spirocyclic β- and γ-Sultams by One-Pot Reductive Cyclization of Cyanoalkylsulfonyl Fluorides

One-pot intramolecular cyclization of novel sp3-enriched cyanoalkylsulfonyl fluorides into spirocyclic β- or γ-sultams is disclosed. The method relies on nitrile group reduction followed by sulfonylation of amino group thus formed upon mild con

Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor

Through a structure-guided rational drug design approach, we have discovered a highly selective inhibitor compound 40 (JSH-150), which exhibited an IC50 of 1 nM against CDK9 kinase in the biochemical assay and achieved around 300–10000-fold selectivity over other CDK kinase family members. In addition, it also displayed high selectivity over other 468 kinases/mutants (KINOMEscan S score(1) = 0.01). Compound 40 displayed potent antiproliferative effects against melanoma, neuroblastoma, hepatoma, colon cancer, lung cancer as well as leukemia cell lines. It could dose-dependently inhibit the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrest the cell cycle and induce the apoptosis in the leukemia cells. In the MV4-11 cell-inoculated xenograft mouse model, 10 mg/kg dosage of 40 could almost completely suppress the tumor progression. The high selectivity and good in vivo PK/PD profile suggested that 40 would be a good pharmacological tool to study CDK9-mediated physiology and pathology as well as a potential drug candidate for leukemia and other cancers.

3-(AMINOARYL)-PYRIDINE COMPOUNDS

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.